Lv7
3710 积分 2020-09-07 加入
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer
9天前
已完结
Microultrasonography-guided prostate cancer biopsy
9天前
已完结
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
9天前
已完结
Targeting the tumour cell surface in advanced prostate cancer
9天前
已完结
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
10天前
已完结
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
2个月前
已完结
Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy
2个月前
已完结
Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials
2个月前
已完结
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
2个月前
已完结
The prostatic middle lobe: clinical significance, presentation and management
3个月前
已完结
皖公网安备34019202002308
